• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Spotlight on Brescia

2018-12-18News

The EPAD family of trial delivery centres grew to 20 sites in August 2018 with Brescia (Italy) enrolling its first research participant. The team of Dr. Samantha Galluzzi (principal investigator of the EPAD project in Brescia) has currently recruited 15 participants in the EPAD Longitudinal Cohort Study (LCS). We caught up with the Brescia team and asked them a few questions about their best practices and recruitment strategies.

Do you have any top tips to share for running the EPAD LCS efficiently at your site? We think that where possible, having a large group of people working on the LCS is the key! In our site we have four cognitive raters, the principal investigator, a study-dedicated sub-investigator, a research nurse and a neurologist in charge to perform the lumbar puncture. This structure gives us the possibility to schedule, in one day, two screening visits (a lot of our eligible subjects who are willing to participate in the study present as a pair e.g. partners, friends or siblings). When we propose that they undergo their visits together, they are really happy and if one of the two is hesitant about his/her participation, usually thanks to this proposal he/she decides to participate. There’s strength in numbers!
At the moment we are the only Italian site joining the EPAD project and thus we have participants coming from all over Italy. One of the last subjects screened, for example, came from a town which is located about 800 km from our hospital. In this case, we unify as far as possible the procedures foreseen by the protocol and we offer to the participants free accommodation to stay in our city. We find that engaging with our participants greatly helps to promote their participation in the study.

How are you able to find suitable subjects for the cohort? We share the main information about the study with other neurologists and geriatricians who work in our hospital or outside. When they visit a patient accompanied by relatives who are apprehensive about developing the same disease, these practitioners talk about the prevention studies and provide them with our contact details. In the waiting room of the outpatient clinics, people can also find materials about the studies on the prevention of the Alzheimer’s disease and people who are interested in joining can also fill out a form to authorise us to contact them in order to provide detailed information about the LCS. Moreover, word of mouth is an effective way for EPAD! The majority of the subjects we screen suggest to their friends or relatives to join themselves. Our team is also involved in other clinical trials and we speak about the EPAD project with the caregivers of the participants who have been joining in one of them.

Any past or future events/conferences which have been beneficial for recruitment into EPAD? We organise quarterly meetings where our principal investigator speaks about Alzheimer’s disease and what we know about the biomarkers. Usually, during these meetings, we show the animated video illustrating the aim of the EPAD project and we explain in more details the procedures required by the protocol. In this way we want to encourage the audience to ask as many questions as they want and express any concerns they may have in regards to the study (usually related to the lumbar puncture). At the end of the meetings, we collect subscriptions to participate. At the meeting organised on 28 November, 30 of the 50 attendees confirmed their interest to take part in the study! Furthermore, before the screening visit we call each participant in order to check the main inclusion/exclusion criteria and, if all the main criteria are respected, we will proceed to schedule the first visit.

“At the moment there are no other Italian site involved in LCS. We hope that soon there would be other TDC recruiting which might contribute to increase the number of Italian subjects in the cohort”, said Michela Rampini, the EPAD study coordinator in Brescia.

Pictured: From left to right: Mihaela Munteanu (research nurse), Ilaria Passeggia (CDR rater), Valentina Saletti (study coordinator), Anna Mega (recruiter), Dr. Samantha Galluzzi (PI), Dr. Alberto Tagliapietra (sub-I), Michela Rampini (study coordinator), Dr. Davide Vito Moretti (sub-I), back left Nicola Lopizzo and Monica Mazzelli (lab technicians), front left Stefania Provasi (lab technicians) and Sara Gipponi (CDR rater). 

EPAD Update

We currently have 20 sites across Europe enrolling and more than 1,300 research participants screened. We are pleased to announce that 118 new research participants were screened in the EPAD LCS in November. This made November our most successful month to date. A special mention goes to CITA (San Sebastian, Spain) and VUmc (Amsterdam, Netherlands) as these teams screened respectively 23 and 19 new research participants in November. We hope that you will share our positive assessment of the continuing progress of this exciting research collaboration. Stay tuned for more news next year. EPAD thanks you all for the hard work within 2018 and wishes you Merry Christmas and a very happy New Year to all of you and your families!

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Analysis of multiple steroids in saliva in the EPAD study
2023-03-02
Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
2023-01-16
Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
2022-12-09
Bruno Steinkraus
Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
2022-11-25
New paper defining and discussing the substantial assets of the EPAD project is out!
2022-11-23
New paper using the EPAD data for an analysis of sleep quality and efficiency
2022-11-03
Latest News
  • Analysis of multiple steroids in saliva in the EPAD study
    2023-03-02
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
    2023-01-16
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
    2022-12-09
  • Bruno Steinkraus
    Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
    2022-11-25
  • New paper defining and discussing the substantial assets of the EPAD project is out!
    2022-11-23
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

📢@imi_epnd has launched its Cohort Catalogue, a central, open & accessible repository for researchers to discover studies & search metadata. Currently 67 research cohorts from 17 countries across Europe including @IMI_EPAD-VUmc participants ⬇️ eurekalert.org/news-releases/… twitter.com/imi_epnd/statu…

reply retweet favorite
9:56 am · 2023-03-14
Twitter
EPAD
EPAD
@IMI_EPAD

NEW paper published in @MetabolitesMDPI using LC-MS/MS method to determine salivary steroids using @IMI_EPAD samples. Congratulations @GregorySarah @zinghomer @guider50 @scottgdenham👏 @EdMassSpecCore @IMI2_NEURONET @IHIEurope #mdpimetabolites mdpi.com/2133518

reply retweet favorite
12:55 pm · 2023-03-02
Twitter
EPAD
EPAD
@IMI_EPAD

"There is a growing consensus that individual research results that are potentially relevant should be reported to research participants” & “Our work was positively received by the EPAD partners, and formed the basis for the set-up & the conduct of the study,” said Eline Bunnik

reply retweet favorite
10:32 am · 2023-01-31
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the @IHIEurope newsletter including a spotlight on IMI results from projects on diabetes @HypoResolve and #Alzheimer’s disease @IMI_EPAD @IMI_AMYPAD ⬇️ Read it: bit.ly/3jeaxdM twitter.com/IHIEurope/stat…

reply retweet favorite
10:30 am · 2023-01-31
Twitter
EPAD
EPAD
@IMI_EPAD

17 centres have contributed to the @IMI_AMYPAD Prognostic Study across 11 Parent Cohorts including @IMI_EPAD. Have a look on the latest AMYPAD paper published in @FrontNeurol ⬇️ twitter.com/IMI_AMYPAD/sta…

reply retweet favorite
8:19 am · 2023-01-30
Workstream Progress
Workstream 120%
Workstream 232%
Workstream 310%
Workstream 446%
Contact us

Submitclear

Recent Posts
  • Analysis of multiple steroids in saliva in the EPAD study
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
  • Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
  • New paper defining and discussing the substantial assets of the EPAD project is out!
Recent Comments
  • The EPAD genomic data is now available on the Alzheimer’s Disease Workbench on The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
  • ADDI celebrates one year of achievements – Neuronet on ADDI celebrates one year of achievements
  • EPAD dataset is now available on the Alzheimer’s Disease Workbench on The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
  • The final EPAD dataset is now available to the entire research community on The final EPAD dataset is now available to the entire research community
  • The ERC has awarded an ERC grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease – Neuronet on New ERC starting grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease
Archives
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • November 2020
  • October 2020
  • September 2020
  • July 2020
  • June 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • June 2015
  • May 2015
  • April 2015
Categories
  • EPAD Academy
  • News
Meta
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT